Sun Pharma inks licensing pact with Aclaris Therapeutics

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases.

Sun Pharma inks licensing pact with Aclaris Therapeutics
Sun Pharma said the agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties. Image Source: Reuters

Sun Pharmaceutical Industries Ltd on Wednesday said its arm has entered into a licensing agreement with Aclaris Therapeutics, Inc that includes upfront payment of USD 15 million (about Rs 125 crore), regulatory and commercial milestones, and royalties.

The agreement has been signed between Sun Pharmaceutical Industries, Inc Aclaris Therapeutics -- a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, the company said in a regulatory filing.

"Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA)," it added.

The company further said, "The agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties."

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

RECOMMENDED STORIES

https://www.zeebiz.com/personal-finance/photo-gallery-power-of-compounding-interest-mutual-fund-sip-retirement-corpus-planning-calculator-how-many-years-it-will-take-to-reach-inr-rs-30000000-with-4000-5000-and-6000-monthly-investment-market-linked-return-324325

Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000

https://www.zeebiz.com/personal-finance/news-sip-mutual-fund-power-of-compounding-retirement-corpus-planning-calculator-salary-inr-rs-25000-per-month-is-it-possible-to-create-over-26367030-fund-calculations-324366

Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations

https://www.zeebiz.com/personal-finance/news-reduce-home-loan-emi-or-reduce-tenure-rs-75-lakh-25-year-home-loan-which-option-can-save-rs-25-lakh-and-64-months-and-how-know-here-324393

Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here

https://www.zeebiz.com/personal-finance/photo-gallery-top-7-large-and-mid-cap-sip-mutual-funds-with-highest-best-xirr-returns-in-5-years-no-1-scheme-has-turned-rs-inr-15000-monthly-investment-into-rs-2054384-uti-icici-hdfc-bank-hsbc-quant-motilal-324344

Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others

https://www.zeebiz.com/markets/stocks/photo-gallery-stock-to-buy-for-long-term-on-new-year-samvat-2081-by-anil-singhvi-iifl-finance-share-price-target-nse-bse-smallcap-stock-324310

New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets

https://www.zeebiz.com/markets/stocks/photo-gallery-share-price-target-of-indian-oil-bharat-petroleum-hindustan-petroleum-largecap-psu-stocks-324329

PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?

https://www.zeebiz.com/personal-finance/photo-gallery-sbi-pnb-hdfc-bank-3-year-senior-citizen-fd-fixed-deposit-interest-rate-maturity-return-calculator-which-bank-gives-highest-on-inr-rs-500000-investment-state-bank-of-india-punjab-national-guaranteed-return-scheme-324094

Senior Citizen FD: SBI 3-year FD vs PNB 3-year FD vs HDFC Bank 3-year FD; which FD will give highest return on Rs 5 lakh investment

Written By: PTI
Updated: Wed, Dec 06, 2023
01:02 PM IST
New Delhi, PTI
RELATED NEWS
Sun Pharma drops 5% after US court halts launch of alopecia treatment drug Sun Pharma drops 5% after US court halts launch of alopecia treatment drug
Sun Pharma Q2 Results Preview: PAT likely to grow 11.5%; gross margin may improve Sun Pharma Q2 Results Preview: PAT likely to grow 11.5%; gross margin may improve
FINAL TRADE: Sensex ends volatile session down 398 pts, Nifty slides to 24,918 dragged by energy, auto shares FINAL TRADE: Sensex ends volatile session down 398 pts, Nifty slides to 24,918 dragged by energy, auto shares

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x